Development of plaque and gingivitis after mouthrinsing with 0.2% delmopinol hydrochloride.

A double-blind, randomized, 2-wk experimental gingivitis clinical trial with cross-over design in 14 dental students was conducted in order to study the efficacy and safety of delmopinol hydrochloride solution (2 mg/ml), used with no other oral hygiene procedures, in comparison with placebo. Plaque formation was measured by the Quigley & Hein Plaque Index and gingivitis was assessed by bleeding on probing according to Mühlemann & Son. Rinsing with delmopinol resulted in lower plaque scores compared to placebo. The development of gingivitis was weak during the 2-wk test periods, and thus no conclusive results were obtained. As in previous studies, the most frequent adverse event when rinsing with delmopinol was a transient anaesthetic sensation in the oral mucosa. The results showed that rinsing with delmopinol hydrochloride solution (2 mg/ml) for 60 s twice daily with no other oral hygiene procedures led to less plaque formation than rinsing with placebo. This study also showed good tolerance and acceptability of mouthrinsing with delmopinol.

Food does not effect in bioavailability of theophylline from Theolin Retard.

The absorption of theophylline from a sustained release tablet preparation ( Theolin Retard 300 mg) was studied in 10 subjects both when fasting and immediately after a standardized breakfast. Intravenous aminophylline was used as the reference material. Food did not influence the absorption from Theolin Retard. The bioavailability was complete (93% after 30 h) both with and without food, and no difference was found in the time to peak of the plasma concentration curve (7 h), or the mean residence time (14 h). The absorption characteristics, with predominantly zero order kinetics, did not change with concomitant intake of breakfast.

Comparison of a sustained-release preparation (Theo-Dur) with a conventional preparation (Nuelin) in the treatment of chronic asthma.

In a double-blind, cross-over trial comprising 19 adult asthmatic patients a sustained-release preparation of theophylline (Theo-Dur), given twice daily, was compared with a conventional fast-release preparation (Nuelin), given three times daily. The theophylline doses were individually titrated to give plasma concentrations in the lower region of the therapeutic interval. The sustained-release preparation gave higher morning theophylline concentrations than the fast-release preparation (9.2 vs 5.9 mg/l). This resulted in somewhat higher morning peak flow values during Theo-Dur treatment. However, the difference in asthma symptoms was not significant and the patients showed no preference for either preparation. We conclude that the advantage of a sustained-release preparation over a conventional fast-release theophylline preparation is the lower dosing frequency rather than the better clinical effect in patients who suffer from chronic asthma, but whose disease is in a relatively stable phase.